Amgen discontinued its early-stage obesity program, dropping AMG-513 as part of pipeline updates. The company did not provide extensive detail on the reason for the termination, but the action shifts Amgen’s obesity strategy toward later-stage candidates, including MariTide. The decision reflects how quickly investor attention and development priorities move in the obesity market after trials and competitive readouts. With multiple next-gen incretin and GLP-1-based strategies advancing simultaneously, early pipeline attrition can also signal recalibration of risk tolerance. For the sector, the pullback may increase competitive pressure on remaining obesity programs while narrowing the set of new candidates expected to reach later clinical phases in the near term.